3. Лечение неоперабельного альвеококкоза печени

Авторы

  • Д.Е. Мукажанов Национальный научный центр хирургии им. А.Н. Сызганова, г. Алматы, Казахстан, Казахский национальный университет имени аль-Фараби, г. Алматы, Казахстан
  • Б.Б. Баймаханов Национальный научный центр хирургии им. А.Н. Сызганова, г. Алматы, Казахстан
  • М.О. Досханов Национальный научный центр хирургии им. А.Н. Сызганова, г. Алматы, Казахстан
  • М.А. Асан Национальный научный центр хирургии им. А.Н. Сызганова, г. Алматы, Казахстан
  • А.Т. Чорманов Национальный научный центр хирургии им. А.Н. Сызганова, г. Алматы, Казахстан
  • Ж.Б. Романова Казахский национальный университет имени аль-Фараби, г. Алматы, Казахстан

DOI:

https://doi.org/10.35805/BSK2023II003

Загрузки

Аннотация

Систематический обзор публикации, по теме диагностики и лечения неоперабельного альвеолярного эхинококкоза печени за последние 30 лет, изучить эффективность различных методов лечения неоперабельного альвеококкоза печени. Мы провели систематический поиск литературных данных и отобрали источники из Google Scholar, PubMed, а также исследовательские работы и учебные онлайн-издания на английском и русском языках. В наш литературный обзор было включено 120 работ, в которых по данным авторов с неоперабельным альвеококкозом печени было описано 883 пациентов, из 120 статей: полных статей - 29, литературных обзоров - 23, описанние клинических случаев – 68. Авторы статецй были из различных стран, таких как: Турция (26%), Франция (24%), Германия (20%), Китай (18%), Англия (6%), Япония (5%) и другие страны Европы и Азии..

Ключевые слова

альвеококкоз, неоперабельный альвеококкоз печени, альбендазол

Библиографические ссылки

  1. Deplazes P., et al. Global Distribution of Alveolar and Cystic Echinococcosis. Advances in Parasitology. 2017. Vol. 95. P.315–493
  2. Craig P., et al. Echinococcosis: control and prevention. Advances in parasitology. 2017. Vol. 96. P.55–158
  3. Stepanova Yu.A., et al. Alveococcosis of the liver: possibilities of ultrasound examination at the stages of combined surgical treatment. 2016. Vol. 118, No
  4. Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis / Bulletin of the World Health Organization. 1996. Vol. 74, №3. P. 231–242
  5. Khachatryan A. Analysis of Lethality in Echinococcal Disease. The Korean journal of parasitology 2017. Vol. 55, №5. P.549–553
  6. McManus D., et al. Yang Diagnosis, treatment, and management of echinococcosis. British medical journal. 2012. Vol. 344. P. e3866
  7. Qu B, et al. Management of Advanced Hepatic Alveolar Echinococcosis: Report of 42 Cases. Am J Trop Med Hyg. 2017;96(3):680-685. doi:10.4269/ajtmh.16-0557
  8. Ozdemir F, et al. Living donor liver transplantation for EchinococcusAlveolaris: single-center experience. Liver Transpl 2015. 21:1091–1095
  9. Mantion GA, et al. Auto-versus allo-transplantation of the liver for end-stage alveolar echinococcosis? Chin Med J 2011, 124:2803–2805
  10. Brunetti E., et al. Writing Panel for the WHO-IWGE2// Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans, doi:10.1016/j.actatropica.2009.11.001
  11. Salm LA, et al. Surgical treatment strategies for hepatic alveolar echinococcosis. Food Waterborne Parasitol. 2019;15:e00050. Published 2019 Apr 5. doi:10.1016/j.fawpar.2019.e00050
  12. Kern P. Clinical features and treatment of alveolar echinococcosis. CurrOpin Infect Dis. 2010; 23:505– 512
  13. Brunetti E, et al. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1–16
  14. Kern P. Human echinococcosis: follow-up of 23 patients treated with mebendazole. Infection 1983; 11:17–24. 50
  15. Ammann RW, et al. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Hepatology 1994; 19:735–742
  16. Bekhti A, et al. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. Br Med J. 1977;2:1047–1051
  17. Dawson M, et al. The effect of dose form on the bioavailability of mebendazole in man. Br J ClinPharmacol. 1985;19:87–90
  18. Ammann RW, et al. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol. 1998;29:994–998
  19. Kern P, et al. Chemotherapy of echinococcosis with mebendazole: clinical observations of 7 patients. Tropenmed Parasitol. 1979;30:65–72
  20. Kung’u A. Glomerulonephritis following chemotherapy of hydatid disease with mebendazole. East Afr Med J. 1982;59:404–409
  21. Kammerer WS, et al. Long term follow-up of human hydatid disease with a high-dose mebendazole regimen. Am J Trop Med Hyg. 1984;33:132–137
  22. Davis A, et al. Multicentre clinical trials of benzimidazole carbamates in human echinococcosis. Bull World Health Organ. 1986;64:383–388
  23. Braithwaite PA, et al. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J ClinPharmacol. 1982;22:161– 169
  24. Reuter S, et al. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J AntimicrobChemother. 2000;46:451–456
  25. Liu CS, et al. Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. Parasitol Res. 2012;111:1205–1211
  26. Vuitton DA. Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus? Expert Rev Anti Infect Ther. 2009;7:145–149
  27. Franchi C, et al. Long-term evaluation of patients with hydatidosis treated with benzimidazolecarbamates. Clin Infect Dis. 1999;29:304–309
  28. Budke CM, et al. Cystic and alveolar echinococcosis: Successes and continuing challenges. PLoSNegl Trop Dis. 2017;11:e0005477
  29. Li H, et al. Chemotherapy in alveolar echinococcosis of multi-organs: what’s the role? Parasitol Res. 2013;112:2237–2243
  30. Karabulut K, et al. Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience. Ann Surg Treat Res. 2014;87:61–65
  31. Salinas JL, et al. Long-term albendazole effectiveness for hepatic cystic echinococcosis. Am J Trop Med Hyg. 2011;85:1075–1079
  32. Bresson-Hadni S, et al. A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J GastroenterolHepatol 2000; 12:327–336
  33. Liu YH, et al. Continuous albendazole therapy in alveolar echinococcosis: long-term follow-up observation of 20 cases. Trans R Soc Trop Med Hyg 2009; 103:768–778
  34. Aydinli B, et al. Alveolar echinococcosis of liver presenting with neurological symptoms due to brain metastases with simultaneous lung metastasis: a case report. Turkiye Parazitol Derg 2008; 32:371–374
  35. Reuter S, et al. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 2004; 39:509–517
  36. Reuter S, et al. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin 2008; 47:147–152
  37. Buttenschoen K, et al. Hepatic infestation of Echinococcus multilocularis with extension to regional lymph nodes. Langenbecks Arch Surg 2009; 394:699–704
  38. Stadelmann B, et al. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. J Antimicrob Chemother 2010; 65:512– 519
  39. Spiliotis M, et al. Axenic in vitro cultivation of Echinococcus multilocu-laris metacestode vesicles and the generation of primary cell cultures. In: Rupp S, Sohn K, editors. Methods in Molecular Biology: Host-Pathogen Interactions. Totowa NJ: Humana Press; 2009. P. 245–262. Treatment of inoperable liver alveococcosis experimental model in stem cell re-search and molecular host-parasite interaction. Parasitology 2010; 137:537–555. This is a fundamental paper on the molecular host–parasite interactions
  40. Stettler M, et al. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47:467–474
  41. Stettler M, et al. Secondary and primary murine alveolar echinococcosis: combined albendazole/ nitazoxanide chemotherapy exhibits profound antiparasitic activity. Int J Parasitol 2004; 34:615– 624
  42. Naguleswaran A, et al. In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multicularis and Echinococcus granulosus. Antimicrob Agents Chemother 2006; 50:3770–3778
  43. Spicher M, et al. In vitro and in vivo effects of 2-methoxyestradiol, either alone or combined with albendazole, against Echinococcus metacestodes. Exp Parasitol 2008; 119:475–482; Epub 2008 Mar 7
  44. Spicher M, et al. In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives. Antimicrob Agents Chemother 2008; 52:3447–3450; Epub 2008 Jul 14
  45. Reuter S, et al. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob Agents Chemother 2003; 47:3586–3591
  46. Kern P, et al. Critical appraisal of nitazoxanide for the treatment of alveolar echinococcosis. Am J Trop Med Hyg 2008; 79:119
  47. Tappe D, et al. Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis. Ann Trop Med Parasitol 2009; 103:177–181
  48. Kern P. Clinical features and treatment of alveolar echinococcosis. Curr Opin Infect Dis. 2010; 23(5):505- 512
  49. Ishizu H, et al. Effect of albendazole on recurrent and residual alveolar echinococ-cosis of the liver after surgery. Hepatology. 1997; 25 (3):528– 531
  50. Bresson-Hadni S, et al. Indications and results of liver transplantation for Echinococcus alveolar infection: an overview. Langenbecks Arch Surg. 2003; 388(4):231- 238
  51. Aliakbarian M, et al. Liver transplantation for hepatic alveolar echinococcosis: literature review and three new cases. Infect Dis (Lond). 2018;50(6):452- 459
  52. Sönmez Ocak, Arzu Poyanlı, Mine Güllüoğu, Cem İbiş, Yaman Tekant, İlgin Özden. Dramatic response to albendazole in transplantation candidates with unresectable hepatic alveolar hydatid disease. Clin Case Rep. 2021;9:e04666. doi.org/10.1002/ ccr3.4666
  53. Mar Siles-Lucas, Adriano Casulli, Roberto Cirilli, David Carmena. Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets. PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006422. doi:10.1371/journal.pntd.0006422
  54. Graeter T, et al. Hepatobiliary complications of alveolar echinococcosis: a long-term follow-up study. World J Gastroenterol. 2015; 21(16):4925–4932
  55. Frei P, et al. Late biliary complications in human alveolar echinococcosis are associated with high mortality. World J Gastroenterol. 2014; 20(19):5881–5888.)
  56. Bresson-Hadni S, et al. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol Int 2006. 55:S267
  57. Bresson-Hadni S, et al. A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol 2000, 12:327–336
  58. Enrico Brunetti, et al. Writing Panel for the WHO-IWGE2//Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans//0001-706X/$ – see front matter, doi:10.1016/j.actatropica.2009.11.001
  59. Ambregna S, et al. A European survey of perendoscopic treatment of biliary complications in patients with alveolar echinococcosis. Expert Rev Anti Infect Ther 2017, 15:79–88
  60. Sato N, et al. Surgery and outcome of alveolar echinococcosis of the liver: historical comparison of mass screening systems in Japan. Int Surg 1997, 82:201–204
  61. Mosimann F. Is alveolar hydatid disease of the liver incurable? Ann Surg 1980, 192:118–123 doi:10.1097/00000658-198007000-00021
  62. Sato N, et al. Contribution of mass screening system to resectability of hepatic lesions involving Echinococcus multilocularis. J Gastroenterol 1997, 32:351–354

Опубликован

2023-05-16

Выпуск

№ 2 (2023)

Раздел

Статьи